PTC
VKTX icon

Private Trust Company’s Viking Therapeutics VKTX Stock Holding History

Private Trust Company’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$3.52K – 2695
2025
Q4 		$3.52K Sell
100
-100
-50% -$3.54K ﹤0.01% 2247
2025
Q3 		$5.26K Hold
200
– – ﹤0.01% 2134
2025
Q2 		$5.3K Hold
200
– – ﹤0.01% 2045
2025
Q1 		$4.83K Sell
200
-50
-20% -$1.58K ﹤0.01% 2044
2024
Q4 		$10.1K Sell
250
-2,078
-89% -$118K ﹤0.01% 1750
2024
Q3 		$147K Sell
2,328
-126
-5% -$7.39K 0.01% 794
2024
Q2 		$130K Buy
2,454
+854
+53% +$56K 0.01% 801
2024
Q1 		$131K Buy
1,600
+1,200
+300% +$53.4K 0.01% 782
2023
Q4 		$7.44K Hold
400
– – ﹤0.01% 1763
2023
Q3 		$4.43K Buy
+400
New +$5.72K ﹤0.01% 1912

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Private Trust Company's VKTX Position: Q1 2026 in Review

Private Trust Company sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 100 shares — an estimated $3.52K sold.

Private Trust Company first reported a position in VKTX in Q3 2023 and held it in 10 quarters. The position peaked at $147K in Q3 2024. 413 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Private Trust Company reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Private Trust Company sold 100 Viking Therapeutics shares in Q1 2026, an estimated $3.52K.
  • Private Trust Company first reported a position in Viking Therapeutics in Q3 2023 and held it in 10 quarters.
  • Private Trust Company's Viking Therapeutics position peaked at $147K in Q3 2024.
  • 413 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Private Trust Company's 13F filing for Q1 2026, filed 30 Apr 2026.